Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide.

作者
Ajay S. Behl,Lorie Ellis,Dominic Pilon,Yongling Xiao,Patrick Lefèbvre
出处
期刊:PubMed [National Institutes of Health]
卷期号:10 (6): 296-303 被引量:37
标识
摘要

BACKGROUND: The efficacy of and overall survival associated with metastatic castration-resistant prostate cancer (CRPC) treatments rely on patients' consistent adherence to the recommended dosage regimens. OBJECTIVES: To evaluate treatment patterns and patient adherence to abiraterone acetate or enzalutamide therapy in real-world practice, and to examine the factors that may be associated with medication dose reduction in patients with metastatic CRPC. METHODS: Retrospective analyses were conducted using the Truven Health MarketScan research databases among patients with metastatic CRPC who initiated treatment with abiraterone acetate or enzalutamide between October 1, 2012, and December 31, 2014 (index date). The patients were followed for up to 12 months, and their baseline characteristics were assessed during the 6 months before the index date. Medication adherence was measured at 3, 6, 9, and 12 months postindex using medication possession ratios (MPRs), and dose reduction was measured using refill gaps and relative dose intensity over the entire observation period. Kaplan-Meier survival analyses and Cox proportional hazards models were used to assess the association between the initial treatment and the risk for dose reduction. RESULTS: The study included 2591 and 807 patients who initiated treatment with abiraterone acetate and enzalutamide, respectively. At 6, 9, and 12 months postindex, the patients who initiated abiraterone acetate had higher MPRs than the patients who initiated enzalutamide. In addition, the patients who initiated abiraterone acetate had lower Kaplan-Meier rates of dose reduction across 4 measurements for dose reduction. All hazard ratios for treatment (abiraterone acetate vs enzalutamide) were significantly lower than 1 (range, 0.57-0.80), indicating a lower risk for dose reduction associated with abiraterone acetate. CONCLUSION: Patients who initiated abiraterone acetate therapy had higher medication adherence and lower risk for dose reduction than those who initiated enzalutamide therapy. Improved medication adherence may be associated with longer duration of treatment, which in turn may lead to better survival. Further research is needed to assess the potential effect of medication adherence on the overall survival of patients with metastatic CRPC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威武的天思完成签到 ,获得积分10
刚刚
刚刚
风吹麦浪的应助被小SCI采纳,获得10
1秒前
Bruce_Wayne发布了新的文献求助10
1秒前
无花果的应助被steforeca采纳,获得10
1秒前
2秒前
sheryy发布了新的文献求助10
2秒前
min发布了新的文献求助10
3秒前
3秒前
nhzz2023发布了新的文献求助10
4秒前
十一发布了新的文献求助10
5秒前
稳重书双完成签到,获得积分10
6秒前
上官若男的应助被笑嘻嘻采纳,获得10
6秒前
Able完成签到 ,获得积分10
7秒前
Maestro_S的应助被平常香采纳,获得10
8秒前
一千根针完成签到 ,获得积分10
9秒前
千里洛完成签到,获得积分10
10秒前
wxg发布了新的文献求助10
11秒前
11秒前
zz完成签到,获得积分10
12秒前
14秒前
领导范儿的应助被zyc采纳,获得10
14秒前
快别闹了发布了新的文献求助10
15秒前
16秒前
传奇3的应助被桃子汽水采纳,获得10
17秒前
标致的问芙完成签到 ,获得积分10
17秒前
小蝴蝶发布了新的文献求助10
18秒前
18秒前
wuwu完成签到,获得积分10
18秒前
冷静完成签到,获得积分10
18秒前
笑嘻嘻发布了新的文献求助10
18秒前
20秒前
李健的应助被武陵济世采纳,获得100
20秒前
20秒前
Redream发布了新的文献求助10
22秒前
木木夕发布了新的文献求助10
22秒前
22秒前
22秒前
lzy完成签到,获得积分10
23秒前
CodeCraft的应助被ly采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183739
求助须知:如何正确求助?哪些是违规求助? 9572996
关于积分的说明 21828615
捐赠科研通 7780904
什么是DOI,文献DOI怎么找? 3434101
关于科研通互助平台的介绍 2558294
邀请新用户注册赠送积分活动 2480564